Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 4, 2016

Date of Report (Date of earliest event reported)

 

Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Florida		000-54933		59-3226705
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.

 

37 North Orange Ave, Suite 607, Orlando, FL		32801
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code 888-613-8802

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ]	Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01 Other Events

 

On November 4, 2016, Immune Therapeutics, Inc. (the “Company”) paid off its Promissory Note with JMJ Financial, disclosed in the Current Form 8K/A filed by the Company on May 4, 2016, in the principal amount of $656,250. These funds came from financing provided by certain of the Company’s current shareholders.

 

On November 14, 2016, the Company issued a press release announcing its intent and efforts to restructure approximately $1,700,000 of its current debt.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are filed herewith.

 

Exhibit No.		Description
99.1		Press Release

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	IMMUNE THERAPEUTICS, INC.
Date: November 15, 2016	By:	/s/ Noreen Griffin
		Noreen Griffin, CEO